Infrastructure for AML treatment in Spain
Debate on the best first-line treatment for unmutated CLL: opinions from across the Atlantic
Developing an understanding of disease progression in MDS and AML
Promising CLL & FL data from ICML 2017: BGB-3111 and obinituzumab
Are complex karyotypes reliable prognostic markers for CLL?